[Skip to Content]
[Skip to Content Landing]
Views 548
Citations 0
Comment & Response
June 20, 2019

Time to Change the Limited-Stage Paradigm for Small Cell Lung Cancer?

Author Affiliations
  • 1Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas, MD Anderson Cancer Center, Houston
  • 2Department of Radiation Oncology, Mayo Clinic Scottsdale, Scottsdale, Arizona
  • 3Department of Radiation Oncology, SUNY Upstate Cancer Center, Syracuse, New York
JAMA Oncol. 2019;5(8):1229. doi:10.1001/jamaoncol.2019.1326

To the Editor To date, the CONVERT trial was one of the largest prospective studies evaluating radiation fractionation in limited-stage small cell lung cancer (SCLC).1 The successful execution of the trial by Faivre-Finn et al1 was a major accomplishment to be envied in the United States, where roughly half of patients with limited-stage SCLC do not even receive radiation as part of initial management.2 Salem et al3 presented a secondary analysis of the CONVERT trial that demonstrated the prognostic value of TNM.

×